Avidicure B.V.
June 17, 2025
Company Presentation
Oncology
153A
Avidicure is a privately held biotechnology company that has developed an entirely new multifunctional antibody modality, "AVC-Boosters", delivering targeted and potent immune-modulating therapy for patients, with broad applicability in oncology and auto-immune diseases.
AVC-Boosters are antibodies designed to safely deliver improved efficacy for a range of complex heterogenous diseases. They combine the best qualities of first-generation antibodies, engagers, checkpoint inhibitors, ADCs and immune cell stimulators. AVC-Boosters drive strong and orchestrated immunological responses, harnessing the full power of the innate and adaptive immune system.
The Company completed a 44 million Euro seed round from a top-tier investor syndicate led by EQT-Life Sciences, with participation from Kurma Partners, BioGeneration Ventures, BOM, Curie Capital and V-Bio Ventures
Company HQ City:
Oegstgeest
Company HQ State:
Zuid-Holland
Company HQ Country:
Netherlands
Year Founded:
2022
Lead Product in Development:
AVC-S-101: TROP2-directed AVC-Booster for treatment of NSCLC, SCLC, Bladder, H&N, EC, TNB
CEO
Arthur Lahr
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
4
When you expect your next catalyst update?
Start first-in-man study
What is your next catalyst (value inflection) update?
Q4 2026
Website
www.avidicure.com
Speakers
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}